𝔖 Bobbio Scriptorium
✦   LIBER   ✦

1123-183 Sustained hemodynamic benefit in patients with pulmonary arterial hypertension after one-year of therapy with the selective orally-active endothelin-A receptor antagonist, sitaxsentan

✍ Scribed by David Langleben; Andrew Hirsch; Eileen Shalit; Lyda Lesenko; Robyn J Barst; Mortimer B Davis


Book ID
119549736
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
265 KB
Volume
43
Category
Article
ISSN
1558-3597

No coin nor oath required. For personal study only.